Sodium Valproate and Diabetic nephropathy
- Conditions
- diabetic nephropathy.Type 2 diabetes mellitus with diabetic nephropathyE11.21
- Registration Number
- IRCT20201023049126N1
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
patients with DMTII
albuminuria more than 30mg/dl
Allergy to valproic acid
Significantly abnormal liver function test
A history of known mental disorders
History of cardiac or liver diseases
Females who were lactating, pregnant, or intending to become pregnant during the study.
A current history of alcohol addiction or drug abuse including analgesics
abnormal blood cells counts
eGFR less than 60 ml/min/1.73m2
hemoglobin A1c more than 8
Blood Pressure more than 160/100 mmHg
neurologic disease such as seizure
use antidepressant or antipsychotic drugs
History of GN, renal stone or other renal disease that induced proteinuria
active hematologic, rheumatologic or infectious diseases
active cancers or tumors
uncontrol hypo or hyper thyroidism
uncontrol hyper parathyroidism
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Microalbuminuria. Timepoint: At the beginning of the study, one month, two months and three months after starting the drug. Method of measurement: Measurement of microalbuminuria of urine samples.
- Secondary Outcome Measures
Name Time Method iver function test. Timepoint: At the beginning of the study, one month, two months and three months after starting the drug. Method of measurement: Using the patient's blood sample.;Complete blood count. Timepoint: At the beginning of the study, one month, two months and three months after starting the drug. Method of measurement: Using the patient's blood sample.